Use of pentoxifylline and tocopherol for the treatment of medical osteonecrosis of the jaw
DOI:
https://doi.org/10.5335/rfo.v29i1.15891Keywords:
Pentoxifilina, Tocoferóis, Osteonecrose da Arcada Osseodentária Associada a DifosfonatoAbstract
Objectives: To evaluate, through a literature review, the effectiveness of the combination of pentoxifylline and tocopherol (PENTO) for the treatment of MRONJ. Literature review: This is a literature review that was carried out in May 2024 in the PubMed (U.S. National Library of Medicine) and VHL (Virtual Health Library) databases, with a time span of 10 years. The search strategy was formulated by combining the descriptors indexed in DeCS/MeSH “Pentoxifylline”, “Tocopherols” and “Bisphosphonate-Associated Osteonecrosis of the Jaw”, combined with the Boolean operator “AND”, and adapted according to the specificities of each data base. The selection criteria were: human studies published in the last 10 years, that answered the guiding question, with full text available in English, Portuguese or Spanish, literature reviews, series or case reports and retrospective studies. The initial search resulted in the identification of 23 articles. Of these, 06 articles were included in the research. Conclusion: Studies demonstrate that the mechanism of action of the PENTO protocol is not yet fully understood, but it appears to be related to the inhibition of inflammation and reduction of fibrosis. This combination has been reported to be well tolerated, with minimal and inexpensive side effects when compared with other non-surgical treatment modalities. The PENTO protocol is effective in the non-invasive treatment of MRONJ.
Downloads
References
Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005;63(11):1567-75.
Ruggiero S, Gralow J, Marx RE, Hoff AO, Schubert MM, Huryn JM, et al. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract. 2006;2(1):7-14.
Eguia A, Bagán-Debón L, Cardona F. Review and update on drugs related to the development of osteonecrosis of the jaw. Med Oral Patol Oral Cir Bucal. 2020;25(1):71-83.
Delfrate G, Mroczek T, Mecca LEA, Andreis JD, Fernandes D, Lipinski LC, et al. Effect of pentoxifylline and α-tocopherol on medication-related osteonecrosis of the jaw in rats: Before and after dental extraction. Arch Oral Biol. 2022;137:105397.
Kuhnt T, Stang A, Wienke A, Vordermark D, Schweyen R, Hey J. Potential risk factors for jaw osteoradionecrosis after radiotherapy for head and neck cancer. Radiat Oncol. 2016;(11):101.
AlDhalaan NA, BaQais A, Al-Omar A. Medication-related Osteonecrosis of the Jaw: A Review. Cureus. 2020;12(2):6944.
Ferreira, BSP. Avaliação da associação pentoxifilina e tocoferol em modelo de osteonecrose dos maxilares induzido pela administração de ácido zoledrônico em ratos. Dissertação (mestrado) – Universidade Federal do Ceará, Faculdade de Medicina, Programa de Pós-Graduação em Ciências Morfofuncionais, Fortaleza, 2021.
He L, Sun X, Liu Z, Qiu Y, Niu Y. Pathogenesis and multidisciplinary management of medication-related osteonecrosis of the jaw. Int J Oral Sci. 2020;12(1):30.
Martos-Fernández M, Saez-Barba M, López-López J, Estrugo-Devesa A, Balibrea-Del-Castillo JM, Bescós Atín C. Pentoxifylline, tocopherol, and clodronate for the treatment of mandibular osteoradionecrosis: a systematic review. Oral Surg Oral Med Oral Pathol Oral Radiol. 201;125(5):431-439.
Pal S, Porwal K, Singh H, Malik MY, Rashid M, Kulkarni C, et al. Reversal of Osteopenia in Ovariectomized Rats by Pentoxifylline: Evidence of Osteogenic and Osteo-Angiogenic Roles of the Drug. Calcif Tissue Int. 2019;105(3):294-307.
Heifetz-Li JJ, Abdelsamie S, Campbell CB, Roth S, Fielding AF, Mulligan JP. Systematic review of the use of pentoxifylline and tocopherol for the treatment of medication-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol. 2019;128(5):491-497.
Owosho AA, Estilo CL, Huryn JM, Yom SK. Pentoxifylline and tocopherol in the management of cancer patients with medication-related osteonecrosis of the jaw: an observational retrospective study of initial case series. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;122(4):455-9.
Magalhães JMI, da Motta Silveira FM, Regueira LS, de Lima E Silva DF, de Andrade Veras SR, de Mello MJG. Pentoxifylline and tocopherol as prophylaxis for osteonecrosis of the jaw due to bone-modifying agents in patients with cancer submitted to tooth extraction: a case series. Support Care Cancer. 2023;31(8):462.
Cavalcante RC, Tomasetti G. Pentoxifylline and tocopherol protocol to treat medication-related osteonecrosis of the jaw: A systematic literature review. J Craniomaxillofac Surg. 2020;48(11):1080-1086.
Magremanne M, Reychler H. Pentoxifylline and tocopherol in the treatment of yearly zoledronic acid-related osteonecrosis of the jaw in a corticosteroid-induced osteoporosis.J Oral Maxillofac Surg. 2014;72(2):334-7.
Carvalho E F, Bertotti M, Migliorati CA, Rocha AC. Cilostazol and Tocopherol in the Management of Medication-Related Osteonecrosis of the Jaw: New Insights From a Case Report. J Oral Maxillofac Surg. 2021;79(12):2499-2506.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Revista da Faculdade de Odontologia - UPF
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
This work is licensed under aCreative Commons Atribuição-NãoComercial-SemDerivações 4.0 Internacional.
